Sean Nolan and RA Session II

Less than 3 months af­ter launch, the AveX­is crew’s Taysha rais­es $95M Se­ries B. Is an IPO next?

The old AveX­is team is mov­ing quick­ly in Dal­las.

Three months ago, they launched Taysha with $30 mil­lion in Se­ries A fund­ing and a pipeline of gene ther­a­pies out of UT South­west­ern. Now, they’ve an­nounced an over­sub­scribed $95 mil­lion Se­ries B. And the biotech is de­clin­ing all in­ter­view re­quests on the news, the kind of broad si­lence that can in­di­cate an IPO is in the pipeline.

Biotechs, in­clud­ing those rel­a­tive­ly fresh off launch, have been go­ing pub­lic at a fren­zy since the pan­dem­ic be­gan. In­vestors have showed a will­ing­ness to put up­wards of $200 mil­lion to com­pa­nies that have yet to bring a drug in­to the clin­ic. Still, if Taysha were to go pub­lic in the near fu­ture, it would be per­haps the short­est path from launch to IPO in re­cent biotech mem­o­ry.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.